Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IGF2R | P11717 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14783446 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL27004807 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL4009422 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL1995711 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL1931658 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL6670386 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL17554435 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL216723 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL502386 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL24021536 | 0.98 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2636749-B1 | NON-REDUCING END-MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | EZAKI GLICO CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| EP-2428578-B1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | EZAKI GLICO CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20130295163-A1 | NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | EZAKI GLICO CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-8575131-B2 | Glucuronic acid-containing glucan, process for production of same, and use of same | NATIONAL UNIVERSITY CORPORATION KAGOSHIMA UNIVERSITY (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2636749-A1 | NON-REDUCING END-MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | Ezaki Glico Co., Ltd. (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-20120135063-A1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | EZAKI GLICO CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2428578-A1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | National University Corporation Kagoshima University (JP) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135063-A1 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME | ENGASE, FUCA1, ALG8 | FBP1 24/4885L3MBTL1 4214/4885IGF2R 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.